Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Tumor Treating Fields: killing two birds with one stone
Juyeun Lee, … , Matthew M. Grabowski, Justin D. Lathia
Juyeun Lee, … , Matthew M. Grabowski, Justin D. Lathia
Published April 15, 2022
Citation Information: J Clin Invest. 2022;132(8):e159073. https://doi.org/10.1172/JCI159073.
View: Text | PDF
Commentary

Tumor Treating Fields: killing two birds with one stone

  • Text
  • PDF
Abstract

Given its aggressive natural history and immunosuppressive nature, glioblastoma (GBM) remains difficult to treat. Tumor Treating Fields (TTFields) are a promising treatment for GBM patients, yet the entirety of their antitumor action has not been fully elucidated. In a recent issue of the JCI, Chen et al. explored the effect of TTFields in reinvigorating immune responses. By elegant step-by-step approaches, the authors demonstrated that TTFields promote the production of immune-stimulating proinflammatory and interferon type 1 cytokines in tumor cells in a cGAS/STING- and AIM2 inflammasome–dependent mechanism, thereby activating the immune system. The findings show that TTFields not only directly inhibit tumor cell growth, as previously reported, but enhance antitumor immunity, suggesting TTFields can be used as an immune-modulating approach in GBM.

Authors

Juyeun Lee, Matthew M. Grabowski, Justin D. Lathia

×

Figure 1

Molecular and cellular mechanisms of TTFields effects on GBM.

Options: View larger image (or click on image) Download as PowerPoint
Molecular and cellular mechanisms of TTFields effects on GBM.
TTFields i...
TTFields induce production of PICs and T1IFNs in cGAS- and AIM2-mediated ways, thereby enhancing anti-GBM immune responses. TTFields, tumor-treating fields; GBM, glioblastoma; TBK1, TANK-binding kinase 1; IRF3, interferon regulatory factor 3; Cas-1, caspase-1; GSDMD, gasdermin D; PICs, proinflammatory cytokines; T1IFNs, type 1 interferons; T1IRGs, type 1 interferon–responsive genes.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts